Imedex: Education is the Best Medicine®

Register for an upcoming conference!

Phone: +1 (678) 242 0906
registration@imedex.com

Lymphoma & Myeloma 2010: An International Congress on Hematologic Malignancies
A comprehensive forum presenting the most recent developments in lymphocytic and plasma cell neoplasms

October 21-23, 2010

New York, New York, USA

The Waldorf=Astoria

Continuing Medical Education

Physicians
Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this educational activity for a maximum 18.0 of AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for Category I credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 18.0 hours of Category I credit for completing this program.

Nurses
This activity has been submitted to the Oncology Nursing Society for approval to award contact hours. ONS is accredited as an approver of continuing nursing education by the American Nurses Credentialing Center’s COA.

Who Should Attend
This educational activity is specifically designed for hematologists, medical oncologists, transplant oncologists, radiation oncologists and other physicians, physicians-in-training, and healthcare professionals (oncology nurses, oncology pharmacy specialists) involved in and/or interested in lymphoma, myeloma and related plasma cell disorders and their management.

Objectives
After attending this congress, participants should be able to:

Summarize clinical trial data regarding at least 4 novel or emerging agents being developed for treatment of relapsed/refractory myeloma
Relate the latest information on how a patient’s eligibility for stem cell transplant affects selection of first-line treatments in myeloma
Restate at least one argument for stem cell transplant as initial treatment and at least one argument for waiting until first relapse
Use the latest information from basic science, transplantation, and clinical research to reduce adverse events and improve outcomes in myeloma patients
Identify at least 1 biochemical signaling pathway that shows therapeutic promise in CLL
Compare and contrast competing standards of care for newly diagnosed and relapsed CLL patients
Recall the most current arguments for and against using prognostic factors to make treatment decisions in CLL
Synthesize the latest information from basic research, laboratory tests, and clinical research to improve outcomes for patients with CLL
Comment on the state of basic science regarding lymphomagenesis
Judge recent attempts to establish a new standard of care for frontline therapy of patients with follicular lymphoma
Use the latest clinical trial data to infer whether it is possible to improve frontline therapy in aggressive lymphoma
Extrapolate upon the latest basic science and clinical research data to extend professional competence when managing patients with NHL

Chairs
Morton Coleman, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

Richard R. Furman, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

John P. Leonard, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

Ruben Niesvizky, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

Faculty
Kenneth C. Anderson, MD, MA
Dana – Farber Cancer Institute
Boston, Massachuetts

Ashraf Badros, MD
University of Maryland
Marlene and Stewart Greenebaum Cancer Center
Baltimore, Maryland

Bart Barlogie, MD, PhD
University of Arkansas Medical Center
Little Rock, Arkansas

Steven H. Bernstein, MD
University of Rochester
Rochester, New York

Joan Blade’, MD
University of Barcelona Hospital Clinic
Barcelona, Spain

George P. Canellos, MD
Dana-Farber Cancer Institute
Boston, Massachussetts

Asher A. Chanan-Khan, MD
Roswell Park Cancer Institute
Buffalo, New York

Selina Chen-Kiang, PhD
Weill Medical College of Cornell University
New York, New York

Morton Coleman, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

Myron S. Czuczman, MD
Roswell Park Cancer Institute
Buffalo, New York

Angela Dipenzieri, MD
Mayo Clinic College of Medicine
Rochester, Minnesota

Rebecca Elstrom, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

Richard R. Furman, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

Ronald Gartenhaus, MD
University of Maryland
Marlene and Stewart Greenebaum Cancer Center
Baltimore, Maryland

Irene M. Ghobrial, MD
Dana-Farber Cancer Institute
Boston, Massachusetts

Sergio Giralt, MD
Memorial Sloan-Kettering Cancer Center
New York, New York

Jean-Luc Harousseau, MD
University of Nantes
Cancer Center of Nantes
Nantes, France

Sundar Jagannath, MD
St. Vincent's Comprehensive Cancer Center
New York, New York

Neil E. Kay, MD
Mayo Clinic
Rochester, Minnesota

Michael J. Keating, MB, BS
The University of Texas
M.D. Anderson Cancer Center
Houston, Texas

Ann LaCasce, MD
Dana-Farber Cancer Institute
Boston, Massachusetts

John P. Leonard, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

David G. Maloney, MD, PhD
Fred Hutchinson Cancer Research Center
Seattle, Washington

Tomer Mark, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

Peter Martin, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

William H. Matsui, MD
Sidney Kummel Comprehensive Cancer Center
John’s Hopkins University
Baltimore, Maryland

Ari Melnick, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

Ruben Niesvizky, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

Owen A. O’Connor, MD, PhD
New York University
Langone Medical Center
New York, New York

Roger Owen, MD
St. James’s Institute of Oncology
Leeds, United Kingdom

Antonio Palumbo, MD
University of Torino
Torino, Italy

Kanti Rai, MD
Long Island Jewish Medical Center
Albert Einstein College of Medicine
New Hyde Park, New York

Paul Richardson, MD
Dana-Farber Cancer Institute
Boston, Massachusetts

Jia Ruan, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

Rita Shaknovich, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

Tait Shanafelt, MD
Mayo Clinic
Rochester, Minnesota

Tsiporah Shore, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

John Sweetenham, MD
Cleveland Clinic
Taussig Cancer Institute
Cleveland, Ohio

Michael Wang, MD
University of Texas
M.D. Anderson Cancer Center
Houston, Texas

Jane Winter, MD
Feinberg School of Medicine
Northwestern University
Chicago, Illinois

Anas Younes, MD
University of Texas
M.D. Anderson Cancer Center
Houston, Texas

Andrew Zelenetz, MD, PhD
Memorial Sloan-Kettering Cancer Center
New York, New York

Thursday – October 21, 2010

8:00 am
Welcome
Mort Coleman, MD

MYELOMA SESSION

8:10 am
Introduction to Myeloma Session
Ruben Niesvizky, MD

Session I: From Bench to Bedside
Moderator: Tomer Mark, MD

8:15 am
Evidence in favor of a myeloma stem cell
William Matsui, MD

8:40 am
Cell Cycle Topic: TBD
Selina Chen-Kiang, PhD

9:00 am
Staging, risk stratification and response evaluation: Do they change our treatment approach and impact prognosis?
Angela Dispenzieri, MD

9:20 am
Panel discussion

9:30 am
Coffee break

Session II: Myeloma Treatment
Moderator: Ruben Niesvizky, MD

9:50 am
What is the best first-line treatment for transplant-eligible patients?
Jean-Luc Harousseau, MD

10:10 am
What is the best first-line treatment for transplant-ineligible patients?
Antonio Palumbo, MD

10:30 am
What is the best treatment for relapsed patients?
Paul Richardson, MD

10:50 am
Extramedullary disease: A fatal condition or is there hope for an effective therapy?
Joan Blade’, MD

11:10 am
Panel discussion

11:30 am
Break for lunch symposium

Session III: Special Considerations in Myeloma
Moderator: Sundar Jagannath, MD

1:30 pm
Renal insufficiency: Cause and impact on treatment selection
Sundar Jagannath, MD

1:45 pm
Osteonecrosis of the jaw: Prevention and treatment
Ashraf Badros, MD

2:00 pm
Thrombogenesis – causes and prevention
Antonio Palumbo, MD

2:15 pm
Panel discussion

Session IV: Special Lectures
Moderator: Morton Coleman, MD

2:25 pm
Presentation of the best Myeloma abstract

2:35 pm
The SASS Foundation for Medical Research Award Ceremony
Francis P. Arena, MD
President & Director of Research for the SASS Foundation

Presentation:
Joseph Michaeli Award for Contributions to Myeloma Research

Presenter:
Paul Richardson, MD

Recipient:
Kenneth C. Anderson, MD

2:45 pm
Going for the cure or is making myeloma a chronic disease good enough?
Kenneth C. Anderson, MD

3:10 pm
Coffee break

Session V: Transplantation
Moderator: Tsiporah Shore, MD

3:30 pm
When should a transplant be performed? As initial treatment or at relapse?
Jean-Luc Harousseau, MD

3:50 pm
Goldie-Coldman/Norton-Simon hypotheses: The embodiment in Total Therapy?
Bart Barlogie, MD, PhD

4:10 pm
Allogeneic transplantation
Sergio Giralt, MD

4:30 pm
Panel discussion

4:45 pm
Adjourn

Friday – October 22, 2010
8:00 am
Welcome

8:05 am
Introduction
Morton Coleman, MD

Session VI: Myeloma and Lymphoproliferative Malignancies: Emerging Agents on Their Way to a Pharmacy Near You
Moderator: Asher Chanan-Khan, MD

8:10 am
Key signal transduction pathways in lymphoma
Ronald Gartenhaus, MD

8:30 am
Novel IMiDs compounds
Asher Chanan-Khan, MD

8:45 am
Novel proteasome inhibitors
Ruben Niesvizky, MD

9:00 am
Novel chemotherapeutic agents
Owen O’Connor, MD, PhD

9:15 am
Novel monoclonal antibodies
Myron Czuczman, MD, PhD

9:30 am
Panel discussion

9:40 am
Coffee break

Session VII: Waldenstrom’s Macroglobulinemia
Moderator: Morton Coleman, MD

10:00 am
The Bruce Waterfall Memorial Lecture: What is the best frontline treatment?
Irene Ghobrial, MD

10:30 am
What is the best treatment for relapsed disease?
Roger G. Owen, MD

10:50 am
Novel approaches to WM
Richard R. Furman, MD

11:10 am
Complications of high IgM - cryoglobulins and hyperviscosity: Plasmapheresis – when is it indicated and how effective is it in both WM and myeloma?
Michael Wang, MD

11:30 am
Panel discussion

11:45 am
Break for lunch symposium

CLL SESSION

Session VIII: From Bench to Bedside
Moderator: Richard R. Furman, MD

1:45 pm
Biology of CLL
Speaker invited

2:05 pm
Biochemical pathways: Targets to be exploited?
Richard R. Furman, MD

2:25 pm
Making the diagnosis: Is monoclonal B cell lymphocytosis a real entity?
Tait D. Shanafelt, MD

2:45 pm
Response evaluation: Is a complete remission necessary or just a surrogate marker for good prognosis?
Michael J. Keating, MB, BS

3:05 pm
Coffee break

Session IX: Special Presentations
Moderator: Morton Coleman, MD

3:25 pm
Presentation of the best CLL abstract

3:35 pm
The SASS Foundation for Medical Research Award Ceremony
Francis P. Arena, MD
President & Director of Research for the SASS Foundation

Presentation:
John Ultmann Award for Contributions to CLL Research

Presenter:
Richard R. Furman, MD and Morton Coleman, MD

Recipient:
Kanti Rai, MD

3:45 pm
Prognostic factors: Do they have a role in treatment decisions and timing?
Kanti Rai, MD

Session X: CLL Treatment
Moderator: Moderator invited

4:05 pm
What is the best frontline approach to treatment?
Neil E. Kay, MD

4:25 pm
What is the best approach for patients who relapse?
Asher Chanan-Khan, MD

4:45 pm
Panel discussion

4:55 pm
Adjourn

Saturday – October 23, 2010

8:00 am
Welcome
Morton Coleman, MD

LYMPHOMA SESSION

8:05 am
Introduction
John P. Leonard, MD

Session XI: Lymphoma Biology and Pathogenesis
Moderator: Rita Shaknovich, MD

8:10 am
Tumor microenvironment and lymphoma pathogenesis
Jia Ruan, MD, PhD

8:30 am
Targeting epigenetics as lymphoma therapy
Ari Melnick, MD

8:50 am
Panel discussion

Session XII: Hodgkin’s Disease
Moderator: Anas Younes, MD

9:00 am
Is radiation an anachronism in Hodgkin’s disease?
George Canellos, MD

9:20 am
ABVD vs. BEACOPP: Can we tailor therapy to fit the patient?
Ann LaCasce, MD

9:40 am
How should we manage the post-transplant, relapsed Hodgkin’s patient?
Anas Younes, MD

10:00 am
Panel discussion

10:15 am
Coffee break

Session XIII: T Cell, Mantle Cell and Marginal Zone Lymphomas
Moderator: Peter Martin, MD

10:45 am
What’s new in T cell lymphoma
Rebecca Elstrom, MD

11:05 am
Sorting through the options for initial management of mantle cell lymphoma
Speaker Invited

11:25 am
How to treat MALT lymphoma failing antibiotics
Andrew Zelenetz, MD

11:45 am
Presentation of the best Lymphoma abstract

12:00 pm
Break for lunch symposium

Session XIV: Follicular Lymphoma
Moderator: John P. Leonard, MD

2:00 pm
Is there a gold standard for the frontline therapy of FL?
David Maloney, MD, PhD

2:20 pm
What are the most promising new agents for B cell lymphoma?
John P. Leonard, MD

2:40 pm
Who should we treat with CNS prophylaxis in DLBCL?
Steven Bernstein, MD

2:55 pm
Panel discussion

3:05 pm
Coffee break

Session XV: Aggressive Lymphoma
Moderator: Rebecca Elstrom, MD

3:25 pm
What is the best initial therapy for Burkitt’s lymphoma?
John Sweetenham, MD

3:45 pm
Optimal initial management of DLBCL
Jane Winter, MD

4:05 pm
Imaging patients with DLBCL: More, less, how?
Rebecca Elstrom, MD

4:25 pm
Treatment of the elderly, relapsing DLBCL patient
Morton Coleman, MD

4:45 pm
Panel discussion

4:55 pm
Adjourn

Participants interested in presenting data should first register or log in, then submit abstracts online by August 12, 2010. Abstracts are subject to acceptance by the Scientific Committee.

Acceptance notifications and guidelines for poster presentation will be sent on September 12, 2010. Authors of accepted abstracts who have not registered will have until October 7, 2010 to do so at the rate of $395.00. After this date, abstracts without registered presenters will be disregarded.

Abstract Guidelines

Follow the online instructions
Abstracts must be written in English
Accepted format: Word document format, 9 point Arial font, 500 word count limit
Use a concise title
List affiliations of author(s) as briefly as possible, with city, state and country
Place an asterisk (*) before the name of the presenting author
Use standard and well-accepted abbreviations
When using references, use standard and well-accepted formats
Abstract content should be single-spaced, typed in lower case and contain:
- Purpose of the study
- Summarized description of the project
- Results and conclusions

Submission Deadline
August 12, 2010

Registration Fees

Physicians Discounted $395
Pharmacists Discounted* $295
If payment received by August 19, 2010

Physicians Regular $495
Pharmacists Regular* $345
If payment received by October 14, 2010

Physicians Full/Onsite $595
Pharmacists Full/Onsite* $395
To register after October 14, 2010

Nurses/Residents/Students* $99
*proof of eligibility must accompany registration
*cannot be combined with any other discounts

To Register: You may register online by October 14, 2010 at www.imedex.com, by calling Imedex at +1 (678) 242 0906 or by returning the registration form in this program by mail or fax. If you mail the form, please keep a copy for your records. Registration confirmations will be issued before the meeting.

To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.

Payment: To pre-register, registration and payment must be received no later than October 14, 2010. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the course is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be made payable to Imedex. Attendee is not registered until full payment is received.

Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the agenda.

Cancellation: For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than October 14, 2010. The amount of registration fees remitted, minus a $75 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after October 14, 2010.

Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

The Waldorf=Astoria
301 Park Avenue
New York, New York 10022
Tel.: +1 (212) 355 3000
Fax: +1 (212) 872 7272
Reservation: (877) 476 8792
www.waldorf.com

As one of the first “grand hotels” to combine luxurious elegance with a myriad of amenities and services, the Waldorf=Astoria has been world renowned for over a century. With a reputation for unparalleled hospitality and service, the Art Deco landmark beckons New Yorkers and visitors alike. Since 1893, The Waldorf=Astoria has epitomized the quintessential luxury hotel experience. Each spacious, individually decorated guest room and suite offers a rewarding union of timeless elegance and up-to-the-moment convenience, luxurious comfort and classic sophistication. The legendary shops of Fifth and Madison Avenues are only minutes away, as are numerous art galleries and specialty shops. The hotel itself is home to some of the world’s most luxurious boutiques.

For the convenience of attendees, a limited number of rooms have been reserved until September 24, 2010 at a discounted rate of $409.00 single/double occupancy, plus tax, currently at 14.25% and a $3.50 per night/per persono ccupancy tax. This rate is not guaranteed outside the conference dates or after September 24, 2010.

To reserve your room please contact the Waldorf=Astoria reservations department at (877) 476 8792 or visit the hotel’s website at www.waldorf.com. To receive the group rate, callers must identify themselves as being with the Lymphoma & Myeloma 2010 group. Internet users must enter the Group/Convention Code: LYM. Reservation requests received after September 24, 2010 may not be guaranteed the group rate.

Letter from the Chairs
Dear Colleague,

It is our pleasure to invite you to join us at Lymphoma & Myeloma 2010: An International Congress on Hematologic Malignancies. This fall’s congress, October 21-23, 2010 will once again be held at the beautiful and historic Waldorf=Astoria in New York, New York.

Since its inception in 2000, this Congress has grown to nearly 1,000 attendees and has become the premier forum on the latest advances in lymphoma, myeloma and related disorders. Using a dynamic approach that features clinical controversies, exciting debates, and intriguing lectures involving examinations of current treatment regimens, attendees will receive a thorough understanding behind the evolution of thought and therapy of lymphoma and myeloma.

Guided by over 30 key opinion leaders in fields of molecular biology, pathology, immunology, and translational and clinical research, this Congress will provide for a stimulating and interactive forum for attendees from all relevant medical specialties who are interested in the developments that lead to improved patient care.

Additionally, attendees will have the added benefit of visiting the cultural melting pot that is New York City during one of the most beautiful times of year. This Congress will be the perfect chance for you to get away and enjoy a weekend of educational activities in the capital city of the world!

We cordially welcome you to our fair city and promise to reward you with an exciting and informative Congress that promises to be our most stimulating yet!

Sincerely,

Morton Coleman, MD, Chair
John P. Leonard, MD, Co-Chair, Lymphoma Session
Ruben Niesvizky, MD, Co-Chair, Myeloma Session
Richard R. Furman, MD, Co-Chair, Leukemia Session

Organizer

Imedex
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com

Chair:
Morton Coleman, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospital
New York, New York

Co-Chair, Lymphoma Session:
John P. Leonard, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospital
New York, New York

Co-Chair, Myeloma Session:
Ruben Niesvizky, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospital
New York, New York

Co-Chair, Leukemia Session:
Richard R. Furman, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospital
New York, New York

Quotes from YOUR colleagues!

Keep up the good work—change nothing
Wonderful Congress; continue to bring in the world’s experts and address [these] difficult topics
All presentations were excellent; it is a privilege to attend
As usual, a great meeting; outstanding quality of presentation; complete and efficient
Congress was superb!
Excellent update – Thanks!
Excellent Congress; I’m not in the field, but look forward to updates
This was my first Imedex-sponsored Congress--excellent program!

Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.

In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.

The following companies have provided an educational grant in support of this conference:

PLATINUM

GOLD

CORPORATE

Several options are available to companies interested in supporting this conference.
For more information, please contact Imedex at +1 (770) 751 7332, or by email at cme@imedex.com.

Information coming soon.

The following companies are exhibitors at this Conference:

Acupath Laboratories, Inc.

Allos

The Binding Site

Celegene

Opportunities are available to companies interested in exhibiting at this conference.
For more information, please contact Cori Gunter at +1 (678) 242 0712, or by email at c.gunter@imedex.com.

Lymphoma & Myeloma 2010: An International Congress on Hematologic Malignancies A comprehensive forum presenting the most recent developments in lymphocytic and plasma cell neoplasms

Organizer

PLATINUM GOLD

CORPORATE

Lymphoma & Myeloma 2010: An International Congress on Hematologic Malignancies
A comprehensive forum presenting the most recent developments in lymphocytic and plasma cell neoplasms

PLATINUM

GOLD